Vaccine Info

Typbar TCV Typhoid Vaccine


Typbar TCV is a vaccine containing polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid.

Vi Capsular polysaccharide of Salmonella typhi alone elicit B cell responses, but the conjugation of bacterial polysaccharide to a protein carrier provides foreign peptide antigens that are presented to the immune system eliciting antigen-specific CD4+ Th cells, referred to as T-dependent antibody responses..


Typbar TCV is indicated as a preventative vaccine against Typhoid which is caused by Salmonella Typhi and Paratyphi.


The WHO recently recommended that routine childhood immunization programs include Typbar TCV as a single intramuscular dose for primary vaccination of infants and children from 6 months of age.

It is also recommended for adults ≤45 years of age and in catch-up campaigns in children ≤15 years of age in typhoid-endemic regions.

Clinical Trials

Clinical Trial NCT03933098: Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine

  • This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose.
  • The study objectives are:

I. Demonstrate non-inferiority of Vi-DT compared to Typbar TCV® as measured by seroconversion rates of anti-Vi IgG ELISA antibody titers, 4 weeks after single dose (pooled immunogenicity of three lots of Vi-DT)

II. Demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT of three lots of Vi-DT vaccine 4 weeks after single dose.

Clinical Trial NCT03600025:  Cellular Immune Responses in Typhoid Fever Patients and Vaccinees (Recruiting)

  • This Phase 1 clinical trial is to further understand the role of mucosal-associated invariant T cell (MAIT) and natural killer (NK) cell responses in typhoid fever or following vaccination. 
  • Transcriptome profiling of human immune responses to S. Typhi infection is not clearly understood.
  • Establishing successful infection by S. Typhi evasion of T cell and neutrophil responses need to be investigated to better understand the correlates of protection.